Essais cliniques

Nous agissons avec l’état d’esprit d’une biotech, tout en bénéficiant des avantages et de l’envergure d’une société biopharmaceutique mondiale. C’est un réel levier pour accroître notre force de développement et notre puissance commerciale dans nos domaines thérapeutiques ciblés. Ipsen s’appuie sur un réseau mondial de professionnels de la santé pour tester de nouveaux médicaments et garantir leur efficacité et leur profil de tolérance en menant des études appelées essais cliniques.

Nos équipes travaillent en étroite collaboration sur les différentes aires thérapeutiques du Groupe, et nous sommes reconnus pour notre expertise mondiale dans les affaires réglementaires, la sécurité des patients et les affaires médicales. Nous avons prouvé notre capacité à apporter, à travers un développement clinique réussi, des solutions thérapeutiques innovantes qui changent la vie des patients.

La liste suivante affiche les essais cliniques interventionnels sponsorisés par Ipsen à venir, en cours de recrutement, actifs ou complétés depuis 2015.
Pour en savoir plus sur les études cliniques disponibles, aller sur : https://clinicaltrials.gov/.
Les résultats des études complétées sont disponibles à partir de 12 mois après la fin de l’étude.
Date de la dernière mise à jour: 02/05/2018







Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly

Phase III Trial | Completed

Conditions : Acromegaly

Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly

PHASE I/II TRIAL | Completed

Conditions : Acromegaly

A Study With Tasquinimod Treating Patients in Four Independent Cohorts of Hepatocellular, Ovarian, Renal Cell and Gastric Cancers

Phase II Trial | Active, not recruiting

Conditions : Advanced or Metastatic Hepatocellular Cancer, Advanced or Metastatic Ovarian Cancer, Metastatic Renal Cell Cancer, Advanced or Metastatic Gastric Carcinoma

Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg

Phase II Trial | Recruiting

Conditions : Pancreatic Tumours, Midgut Neuroendocrine Tumours

A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.

Phase IV Trial | Active, not recruiting

Conditions : Prostate Cancer

Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumors

Phase III Trial | Recruiting

Conditions : Neuroendocrine Tumors

Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis

Phase III Trial | Recruiting

Conditions : Endometriosis

Chronic Administration of Diosmectite (SMECTA®) in Subjects With Chronic Diarrhoea

Phase I Trial | Completed

Conditions : Chronic Functional Diarrhea of Unknown Origin

Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Insufficiency and Matched Healthy Subjects

Phase I Trial | Completed

Conditions : Hepatic Impairment

To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour

Phase II Trial | Recruiting

Conditions : Gastro-Enteropancreatic Neuroendocrine Tumor

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPSC001 in NETs

PHASE I/II TRIAL | Recruiting

Conditions : Neuroendocrine Tumors

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1

Phase III Trial | Recruiting

Conditions : Urinary Incontinence, Overactive Bladder

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2

Phase III Trial | Recruiting

Conditions : Urinary Incontinence, Overactive Bladder

Efficacy of Diosmectite (Smecta®) in the Symptomatic Treatment of Acute Diarrhoea in Adults

Phase IV Trial | Recruiting

Conditions : Acute Diarrhoea

Study to Evaluate Effects of DYSPORT® Injected in Lower and Upper Limb Combined With Guided Self-Rehabilitation Contract (GSC)

Phase IV Trial | Active, not recruiting

Conditions : Spastic Hemiparesis

Efficacy, Safety and Tolerability of Eziclen®/Izinova® Versus Klean-prep® on Bowel Cleansing in Adolescents Undergoing Colonoscopy

Phase III Trial | Recruiting

Conditions : Digestive System Disease

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

Phase I Trial | Active, not recruiting

Conditions : Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis

Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer

PHASE II/III TRIAL | Not Yet recruiting

Conditions : Small Cell Lung Cancer

Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

PHASE I/II TRIAL | Recruiting

Conditions : Pancreatic Cancer

Efficacy And Safety Of Dysport In The Treatment Of Upper Limb Spasticity In Children

Phase III Trial | Active, not recruiting

Conditions : Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children

Dysport in the Treatment of Glabellar Lines in Chinese Subjects

Phase III Trial | Completed

Conditions : Glabellar Lines

Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines

Phase III Trial | Completed

Conditions : Moderate to Severe Glabellar Lines

Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines

Phase III Trial | Completed

Conditions : Glabellar Lines